ATNM (Actinium Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Actinium Pharmaceuticals's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Actinium Pharmaceuticals's Operating Income for the three months ended in Dec. 2024 was $ -7.51 Mil. Actinium Pharmaceuticals's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate Actinium Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Actinium Pharmaceuticals Interest Expense Historical Data

The historical data trend for Actinium Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Interest Expense Chart

Actinium Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

Actinium Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Actinium Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Actinium Pharmaceuticals (AMEX:ATNM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Actinium Pharmaceuticals's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-7.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.99 Mil.

Actinium Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Actinium Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Actinium Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Actinium Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

7AY1:Germany

Address

100 Park Avenue, 23rd Floor, New York, NY, USA, 10017

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Executives

Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin	officer: VP, Finance and Corporate Dev.	955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig	officer: Chief Scientific Officer	21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell	director	521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty	director	643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur	officer: Chief Commercial Officer	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray	officer: Executive Vice President	14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center	10 percent owner	1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa	director	138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave	director, officer: President and CEO	4 WATER STREET, EDISON NJ 08820
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc	10 percent owner	C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd.	10 percent owner	C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000